» Articles » PMID: 22046321

Improved Adsorption of an Enterococcus Faecalis Bacteriophage ΦEF24C with a Spontaneous Point Mutation

Overview
Journal PLoS One
Date 2011 Nov 3
PMID 22046321
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Some bacterial strains of the multidrug-resistant Gram-positive bacteria Enterococcus faecalis can significantly reduce the efficacy of conventional antimicrobial chemotherapy. Thus, the introduction of bacteriophage (phage) therapy is expected, where a phage is used as a bioagent to destroy bacteria. E. faecalis phage ΦEF24C is known to be a good candidate for a therapeutic phage against E. faecalis. However, this therapeutic phage still produces nonuniform antimicrobial effects with different bacterial strains of the same species and this might prove detrimental to its therapeutic effects. One solution to this problem is the preparation of mutant phages with higher activity, based on a scientific rationale. This study isolated and analyzed a spontaneous mutant phage, ΦEF24C-P2, which exhibited higher infectivity against various bacterial strains when compared with phage ΦEF24C. First, the improved bactericidal effects of phage ΦEF24C-P2 were attributable to its increased adsorption rate. Moreover, genomic sequence scanning revealed that phage ΦEF24C-P2 had a point mutation in orf31. Proteomic analysis showed that ORF31 (mw, 203 kDa) was present in structural components, and immunological analysis using rabbit-derived antibodies showed that it was a component of a long, flexible fine tail fiber extending from the tail end. Finally, phage ΦEF24C-P2 also showed higher bactericidal activity in human blood compared with phage ΦEF24C using the in vitro assay system. In conclusion, the therapeutic effects of phage ΦEF24C-P2 were improved by a point mutation in gene orf31, which encoded a tail fiber component.

Citing Articles

Characterization of phage evolution and phage resistance in drug-resistant .

Han P, Lin W, Fan H, Tong Y J Virol. 2024; 98(2):e0124923.

PMID: 38189285 PMC: 10878236. DOI: 10.1128/jvi.01249-23.


Bacteriolytic Potential of Phage iF6 Isolated from "Sextaphag" Therapeutic Phage Cocktail and Properties of Its Endolysins, Gp82 and Gp84.

Buzikov R, Kazantseva O, Piligrimova E, Ryabova N, Shadrin A Viruses. 2023; 15(3).

PMID: 36992476 PMC: 10054541. DOI: 10.3390/v15030767.


Phenotypic Characterization and Comparative Genomic Analysis of Novel Bacteriophages Isolated from a Tropical Rainforest.

Mutusamy P, Singh K, Yin L, Petersen B, Sicheritz-Ponten T, Clokie M Int J Mol Sci. 2023; 24(4).

PMID: 36835084 PMC: 9963771. DOI: 10.3390/ijms24043678.


Genomic characterization of a new phage BUCT541 against K1-ST23 and efficacy assessment in mouse and larvae.

Pu M, Li Y, Han P, Lin W, Geng R, Qu F Front Microbiol. 2022; 13:950737.

PMID: 36187954 PMC: 9523250. DOI: 10.3389/fmicb.2022.950737.


In Vitro Techniques and Measurements of Phage Characteristics That Are Important for Phage Therapy Success.

Glonti T, Pirnay J Viruses. 2022; 14(7).

PMID: 35891470 PMC: 9323186. DOI: 10.3390/v14071490.


References
1.
Eliopoulos G . Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. J Infect. 2009; 59 Suppl 1:S17-24. DOI: 10.1016/S0163-4453(09)60004-9. View

2.
POWERS J . Antimicrobial drug development--the past, the present, and the future. Clin Microbiol Infect. 2004; 10 Suppl 4:23-31. DOI: 10.1111/j.1465-0691.2004.1007.x. View

3.
Letkiewicz S, Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Gorski A . Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis--case report. Folia Microbiol (Praha). 2009; 54(5):457-61. DOI: 10.1007/s12223-009-0064-z. View

4.
Kayser F . Safety aspects of enterococci from the medical point of view. Int J Food Microbiol. 2003; 88(2-3):255-62. DOI: 10.1016/s0168-1605(03)00188-0. View

5.
Hyman P, Abedon S . Bacteriophage host range and bacterial resistance. Adv Appl Microbiol. 2010; 70:217-48. DOI: 10.1016/S0065-2164(10)70007-1. View